Cargando…

Risk and promise: an 11-year, single-center retrospective study of severe acute GVHD in pediatric patients undergoing allogeneic HSCT for nonmalignant diseases

BACKGROUND: Hematopoietic stem cell transplantation (HSCT) is the only curative option for many nonmalignant hematopoietic-derived diseases in pediatric patients. Survival after HSCT has improved in recent years and resulted in a 90% survival rate and cure in some nonmalignant diseases. Graft-vs.-ho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zaidman, Irina, Even-Or, Ehud, Aharoni, Elroee, Averbuch, Dina, Dinur-Schejter, Yael, NaserEddin, Adeeb, Slae, Mordechai, Shadur, Bella, Stepensky, Polina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pediatrics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250657/ https://www.ncbi.nlm.nih.gov/pubmed/37303759 http://dx.doi.org/10.3389/fped.2023.1194891

Ejemplares similares

Haploidentical stem cell transplantation with post-transplant cyclophosphamide for osteopetrosis and other nonmalignant diseases
por: Even-Or, Ehud, et al.
Publicado: (2020)

Autoimmune Cytopenias Post Hematopoietic Stem Cell Transplantation in Pediatric Patients With Osteopetrosis and Other Nonmalignant Diseases
por: Even-Or, Ehud, et al.
Publicado: (2022)

Neurological complications following pediatric allogeneic hematopoietic stem cell transplantation: Risk factors and outcome
por: Zaidman, Irina, et al.
Publicado: (2022)

Bacillus Calmette–Guerin (BCG) Vaccine-associated Complications in Immunodeficient Patients Following Stem Cell Transplantation
por: NaserEddin, Adeeb, et al.
Publicado: (2020)

Two decades of stem cell transplantation in patients with Fanconi anemia: Analysis of factors affecting transplant outcomes
por: Fink, Orly, et al.
Publicado: (2022)

A human case of GIMAP6 deficiency: a novel primary immune deficiency
por: Shadur, Bella, et al.
Publicado: (2020)

The Clinical Aspect of Adaptor Molecules in T Cell Signaling: Lessons Learnt From Inborn Errors of Immunity
por: Dinur-Schejter, Yael, et al.
Publicado: (2021)

The Evidence for Allogeneic Hematopoietic Stem Cell Transplantation for Congenital Neutrophil Disorders: A Comprehensive Review by the Inborn Errors Working Party Group of the EBMT
por: Bakhtiar, Shahrzad, et al.
Publicado: (2019)

Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC study
por: Achini-Gutzwiller, Federica R., et al.
Publicado: (2023)

Pathophysiology of GvHD and Other HSCT-Related Major Complications
por: Ghimire, Sakhila, et al.
Publicado: (2017)

Late Endocrine Effects After HSCT in Children With Nonmalignant Diseases; A Single Center Cohort Analysis
por: de Kloet, Liselotte C, et al.
Publicado: (2021)

Oral Cancer in HSCT Pediatric Patients Arising on GVHD: A Comprehensive Review
por: Cantile, Tiziana, et al.
Publicado: (2022)

Targeting SLP76:ITK interaction separates GVHD from GVL in allo-HSCT
por: Mammadli, Mahinbanu, et al.
Publicado: (2021)

TCRαβ/CD19 depleted HSCT from an HLA-haploidentical relative to treat children with different nonmalignant disorders
por: Merli, Pietro, et al.
Publicado: (2022)

Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT
por: Mammadli, Mahinbanu, et al.
Publicado: (2020)

A nomogram model for predicting ocular GVHD following allo-HSCT based on risk factors
por: Wang, Wen-hui, et al.
Publicado: (2023)

Autoimmune Complications after Hematopoietic Stem Cell Transplantation in Children with Nonmalignant Disorders
por: Khalil, Abdalla, et al.
Publicado: (2014)

Evaluation of Cyclosporine Pharmacokinetic, Monitoring, and Dosing Parameters for GVHD Prophylaxis in Hematopoietic Stem Cell Transplant (HSCT) Recipients
por: Tafazoli, Ali, et al.
Publicado: (2019)

Nonmalignant leukocyte disorders
por: Marionneaux, Steven
Publicado: (2020)

PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients
por: Hossain, Mohammad S., et al.
Publicado: (2017)

GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma
por: Muranushi, Hiroyuki, et al.
Publicado: (2020)

Establishment of a predictive model for GVHD-free, relapse-free survival after allogeneic HSCT using ensemble learning
por: Iwasaki, Makoto, et al.
Publicado: (2022)

Post-transplant cyclophosphamide for GVHD prophylaxis in pediatrics with chronic active Epstein-Barr virus infection after haplo-HSCT
por: Luo, Rongmu, et al.
Publicado: (2022)

A Green Light for Stop Mutations
por: Cohen-Cymberknoh, Malena, et al.
Publicado: (2021)

PD-1 Checkpoint Blockade in Patients for Acute Myeloid Leukemia after HSCT Relapse Resulted in Severe GVHD and sHLH
por: Du, Zhi zhuo, et al.
Publicado: (2022)

Nonmalignant Features Associated with Inherited Colorectal Cancer Syndromes-Clues for Diagnosis
por: Haimov, Diana, et al.
Publicado: (2022)

Blood Stream Infection (BSI) and Acute Graft Versus Host Disease (GVHD) after Hematopoietic Stem Cell Transplantation (HSCT) are Associated
por: Poutsiaka, Debra D, et al.
Publicado: (2010)

BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT
por: Copsel, Sabrina N., et al.
Publicado: (2019)

Early CD8(+)-recovery independently predicts low probability of disease relapse but also associates with severe GVHD after allogeneic HSCT
por: Ranti, Juha, et al.
Publicado: (2018)

Steroid-resistant intestinal aGVHD and refractory CMV and EBV infections complicated by haplo-HSCT were successfully rescued by FMT and CTL infusion
por: Qi, Ling, et al.
Publicado: (2021)

Pre-transplant CD69+ extracellular vesicles are negatively correlated with active ATLG serum levels and associate with the onset of GVHD in allogeneic HSCT patients
por: Storci, Gianluca, et al.
Publicado: (2023)

Therapeutic Effects of HLA-G5 Overexpressing hAMSCs on aGVHD After Allo-HSCT: Involving in the Gut Microbiota at the Intestinal Barrier
por: Bu, Xiaoyin, et al.
Publicado: (2023)

Human Amniotic Mesenchymal Stem Cells Alleviate aGVHD after allo-HSCT by Regulating Interactions between Gut Microbiota and Intestinal Immunity
por: Bu, Xiaoyin, et al.
Publicado: (2023)

Lymphocyte counts may predict a good response to mesenchymal stromal cells therapy in graft versus host disease patients
por: Hinden, Liad, et al.
Publicado: (2019)

Efficacy of palifermin on oral mucositis and acute GVHD after hematopoietic stem cell transplantation (HSCT) in hematology malignancy patients: a meta-analysis of trials
por: Mozaffari, Hamid Reza, et al.
Publicado: (2017)

Palliative Care for Patients with Nonmalignant Respiratory Disease
por: Gupta, Nishkarsh, et al.
Publicado: (2017)

Medical Cannabis for Chronic Nonmalignant Pain Management
por: Hameed, Maha, et al.
Publicado: (2023)

Pleural effusion due to nonmalignant gastrointestinal disease
por: Ferreiro, Lucía, et al.
Publicado: (2023)

SARS-CoV-2 Infection and Active, Multiorgan, Severe cGVHD After HSCT for Adolescent ALL: More Luck Than Understanding? A Case Report
por: Zubarovskaya, Natalia, et al.
Publicado: (2022)

Posttransplant de novo DSA and NDSA affect GvHD, OS, and DFS after haplo-HSCT in patients without pre-existing HLA antibodies of hematological malignancies
por: Wang, Lan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p2hv3kkc86tdil8hkcv69217da